Laboratorios Farmaceuticos Rovi, S.A. (LABFF)

Market Cap	3.91B +20.2%
Revenue (ttm)	940.94M +14.4%
Net Income	233.44M +69.7%
EPS	4.50
Shares Out	n/a
PE Ratio	14.93
Forward PE	21.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	67.17
Previous Close	67.17
Day's Range	67.17 - 90.61
52-Week Range	67.17 - 90.61
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About LABFF

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,470
• Stock Exchange: OTCMKTS
• Ticker Symbol: LABFF

Financial Performance

In 2025, LABFF's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error